A revised version of the US Centers for Disease Control and Prevention’s coronavirus diagnostic was reauthorized by the Food and Drug Administration on 15 March, FDA commissioner Stephen Hahn announced in a 16 March series of tweets.
The CDC’s test, known as the CDC 2019-Novel Coronavirus Real-Time Reverse Transcriptase RT-PCR Diagnostic Panel, was initially authorized by the FDA on 4 February under its Emergency Use Authorization (EUA) process
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?